Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Date

Click to order products descending

Display 15 Products per page

2015 Chronic Lymphocytic Leukemia (CLL) KOL Interview

$599.00

Following our live coverage of ASH, we interviewed a KOL who specializes in treating lymphoid malignancies to provide further insight on current and future paradigms for the treatment of CLL and NHLs.
January 28, 2015
Find out more
2015 Chronic Lymphocytic Leukemia (CLL) Pulse

$599.00

We performed a 5-question survey of 40 hematology-oncology specialists in the US to gauge current prescribing practices and physician experience with reimbursement for ibrutinib and idelalisib for the treatment of patients with CLL.
January 27, 2015
Find out more
2014 Community-Acquired Pneumonia Pulse

$599.00

We performed a 5-question survey of 20 infectious disease (ID) specialists in the U.S. to gauge current prescribing practices for community-acquired pneumonia (CAP) and gauge interest in new drugs/new drug candidates.
December 18, 2014
Find out more
Post-AASLD US KOL Interview

$599.00

Over 95% SVR for easy-to-treat patients, and it’s one pill a day for 8-12 weeks for most. In that context, the only way you can improve up on that is to improve care for all populations, not just for easy-to-treat but the difficult-to-treat: decompensated cirrhotics, the post-transplant, and HIV co-infected patients.
December 16, 2014
Find out more
Ebola KOL Interview #3

$599.00

Ebola KOL Interview #3
December 2, 2014
Find out more
U.S. Disease Incidence and Prevalence

$4,750.00

This comprehensive report examines the etiology and epidemiology, number of hospital discharges, incidence and prevalence, and mortality rates of the most prevalent diseases/disorders in the United States for the years 2000-2010, and 2013.
November 3, 2014
Find out more
Ebola KOL Interview #1

$599.00

So the history in Africa has been very extensive since the 1970s and outbreaks in those countries havehappened sporadically over the last 40 years. Here in US, right, this is our first case of anyone being sick with Ebola, and there are a number of people who have actually come into the country.
November 2, 2014
Find out more
Dermatology KOL Interview

$599.00

BioMedTracker – Dermatology KOL Interview In recent years, patients have become more comfortable with aesthetic dermatology procedures as they have become more widespread.
October 31, 2014
Find out more
2014 October Dermatology Survey

$599.00

We performed a 5-question survey of 21 dermatologists to gauge usage of drugs and devices for the treatment of common dermatological conditions and for aesthetic procedures.
October 30, 2014
Find out more
Multiple Sclerosis KOL Insight Interview

$599.00

Multiple Sclerosis KOL Insight Interview
October 28, 2014
Find out more
Retinal Disorders (AMD and DME) Pulse

$599.00

We performed a 5-question survey of 20 ophthalmologists who treat retinal diseases to gauge current usage and projected future usage of agents for the treatment of wet and dry age-related macular degeneration (AMD) and diabetic macular edema (DME).
October 27, 2014
Find out more
Zelapar
Read More
Zelapar (selegiline; Valeant) is a novel rapidly disintegrating tablet formulation of the monoamine oxidase B (MAO-B) inhibitor selegiline.
October 24, 2014
Find out more
Inpatient Infections Pulse

$599.00

We conducted a survey of 20 infectious diseases specialists to evaluate current drug usage for the treatment of selected severe/inpatient infections and gauge physician interest in new drugs.
October 8, 2014
Find out more
Cubicin
Read More
Cubicin is a cyclic lipopeptide antibacterial that has a unique mechanism of action. It causes rapid depolarization of the bacterial cell membrane potential upon binding to the membrane.
September 10, 2014
Find out more
Orbactiv
Read More
Orbactiv is a broad-spectrum antibiotic mainly targeting inpatient settings. The drug is a semisynthetic lipoglycopeptide that inhibits bacterial cell wall synthesis by blocking peptidoglycan biosynthesis.
September 10, 2014
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *